169 related articles for article (PubMed ID: 20619457)
1. Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics.
Borbulevych OY; Do P; Baker BM
Mol Immunol; 2010 Sep; 47(15):2519-24. PubMed ID: 20619457
[TBL] [Abstract][Full Text] [Related]
2. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
Pinilla-Ibarz J; May RJ; Korontsvit T; Gomez M; Kappel B; Zakhaleva V; Zhang RH; Scheinberg DA
Leukemia; 2006 Nov; 20(11):2025-33. PubMed ID: 16990779
[TBL] [Abstract][Full Text] [Related]
3. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
4. Non-natural and photo-reactive amino acids as biochemical probes of immune function.
Gómez-Nuñez M; Haro KJ; Dao T; Chau D; Won A; Escobar-Alvarez S; Zakhaleva V; Korontsvit T; Gin DY; Scheinberg DA
PLoS One; 2008; 3(12):e3938. PubMed ID: 19079589
[TBL] [Abstract][Full Text] [Related]
5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
6. Computational analysis on the binding of epitope peptide to human leukocyte antigen class I molecule A*2402 subtype.
Mahmood MD; Matsuo Y; Neya S; Hoshino T
Chem Pharm Bull (Tokyo); 2011; 59(10):1254-62. PubMed ID: 21963635
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
Chaise C; Buchan SL; Rice J; Marquet J; Rouard H; Kuentz M; Vittes GE; Molinier-Frenkel V; Farcet JP; Stauss HJ; Delfau-Larue MH; Stevenson FK
Blood; 2008 Oct; 112(7):2956-64. PubMed ID: 18502835
[TBL] [Abstract][Full Text] [Related]
8. Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.
Busse A; Letsch A; Scheibenbogen C; Nonnenmacher A; Ochsenreither S; Thiel E; Keilholz U
J Transl Med; 2010 Jan; 8():5. PubMed ID: 20092642
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
10. Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol.
Knights AJ; Zaniou A; Rees RC; Pawelec G; Müller L
Cancer Immunol Immunother; 2002 Jul; 51(5):271-81. PubMed ID: 12070714
[TBL] [Abstract][Full Text] [Related]
11. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
Borbulevych OY; Baxter TK; Yu Z; Restifo NP; Baker BM
J Immunol; 2005 Apr; 174(8):4812-20. PubMed ID: 15814707
[TBL] [Abstract][Full Text] [Related]
12.
Schmidt J; Guillaume P; Dojcinovic D; Karbach J; Coukos G; Luescher I
J Biol Chem; 2017 Jul; 292(28):11840-11849. PubMed ID: 28536262
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.
van der Burg SH; Visseren MJ; Brandt RM; Kast WM; Melief CJ
J Immunol; 1996 May; 156(9):3308-14. PubMed ID: 8617954
[TBL] [Abstract][Full Text] [Related]
14. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design.
Schiewe AJ; Haworth IS
J Mol Graph Model; 2007 Oct; 26(3):667-75. PubMed ID: 17493854
[TBL] [Abstract][Full Text] [Related]
15. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
16. WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignancies.
Li Z; Oka Y; Tsuboi A; Masuda T; Tatsumi N; Kawakami M; Fujioka T; Sakaguchi N; Nakajima H; Fujiki F; Udaka K; Oji Y; Kawase I; Sugiyama H
Int J Hematol; 2005 Dec; 82(5):458-9. PubMed ID: 16533753
[No Abstract] [Full Text] [Related]
17. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
[TBL] [Abstract][Full Text] [Related]
18. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
Wang Z; Turner R; Baker BM; Biddison WE
J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.
Al Qudaihi G; Lehe C; Negash M; Al-Alwan M; Ghebeh H; Mohamed SY; Saleh AJ; Al-Humaidan H; Tbakhi A; Dickinson A; Aljurf M; Dermime S
Leuk Lymphoma; 2009 Feb; 50(2):260-9. PubMed ID: 19197722
[TBL] [Abstract][Full Text] [Related]
20. Structure of celiac disease-associated HLA-DQ8 and non-associated HLA-DQ9 alleles in complex with two disease-specific epitopes.
Moustakas AK; van de Wal Y; Routsias J; Kooy YM; van Veelen P; Drijfhout JW; Koning F; Papadopoulos GK
Int Immunol; 2000 Aug; 12(8):1157-66. PubMed ID: 10917890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
